Martin van der Valk

8.6k citations

45 papers · 6.9k indexed · 4 hit papers · h-index 33

Molecular Biology top 2%
Oncology top 0.5%
Genetics top 2%
Cancer Research top 2%
Pediatrics, Perinatology and Child Health top 1%

Co-authors: Anton Berns Hein te Riele Ralph Meuwissen Jos Jonkers Els C. Robanus-Maandag Hanneke van der Gulden Hans Peterse Jos Domen
Topics: Cancer-related Molecular Pathways (7 papers)Drug Transport and Resistance Mechanisms (7 papers)Pharmacological Effects and Toxicity Studies (6 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Nature Journal of Clinical Investigation Nature Medicine
Partner nations: Netherlands United States France

In The Last Decade

Martin van der Valk

45 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Requirement for a functional Rb-1 gene in murine development

1992 840 citations Alan R. Clarke, Nathalie M. T. van der Lugt et al. Nature profile →
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

2001 794 citations Jos Jonkers, Ralph Meuwissen et al. Nature Genetics profile →
Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene.

1994 644 citations Jos Domen, Els C. Robanus-Maandag et al. Genes & Development profile →
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

2002 590 citations John Allen, Martin van der Valk et al. profile →

Peers

Countries citing papers authored by Martin van der Valk

Since Specialization

Citations

This map shows the geographic impact of Martin van der Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin van der Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin van der Valk more than expected).

Fields of papers citing papers by Martin van der Valk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin van der Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin van der Valk. The network helps show where Martin van der Valk may publish in the future.

Co-authorship network of co-authors of Martin van der Valk

This figure shows the co-authorship network connecting the top 25 collaborators of Martin van der Valk. A scholar is included among the top collaborators of Martin van der Valk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin van der Valk. Martin van der Valk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation 2019 ·Archives of Toxicology ·Selvi Durmuş,Martin van der Valk,(unknown),Ji-Ying Song,Els Wagenaar,Jos H. Beijnen,Alfred H. Schinkel	10
2	OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice 2013 ·Molecular Cancer Therapeutics ·Dilek Iusuf,Marion Ludwig,Ahmed M.O. Elbatsh,Anita van Esch,Evita van de Steeg,Els Wagenaar,Martin van der Valk,Fan Lin,Olaf van Tellingen,Alfred H. Schinkel	35
3	Targeting BRAF in an Inducible Murine Model of Melanoma 2012 ·American Journal Of Pathology ·Anna I. Hooijkaas,Jules Gadiot,Martin van der Valk,Wolter J. Mooi,Christian U. Blank	49
4	A Targeted Constitutive Mutation in the Apc Tumor Suppressor Gene Underlies Mammary But Not Intestinal Tumorigenesis 2009 ·PLoS Genetics ·Cláudia Gaspar,Patrick Franken,(unknown),Cor Breukel,Martin van der Valk,Ron Smits,Riccardo Fodde	62
5	Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M 2009 ·Human Molecular Genetics ·Sietske T. Bakker,Henri J. van de Vrugt,Martin A. Rooimans,Anneke B. Oostra,Jûrgen Steltenpool,(unknown),(unknown),Martin van der Valk,Hans Joenje,Hein te Riele,Johan P. de Winter	108
6	Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides 2005 ·Journal of Hepatology ·Noam Zelcer,Koen van de Wetering,Rudi de Waart,George L. Scheffer,Hanns–Ulrich Marschall,Peter R. Wielinga,Annemieke Kuil,Cindy Kunne,Alexander J. Smith,Martin van der Valk,Jan Wijnholds,Ronald Oude Elferink,Piet Borst	138
7	Smad4 haploinsufficiency in mouse models for intestinal cancer 2005 ·Oncogene ·Paola Alberici,(unknown),Emma de Pater,Martin van der Valk,Ron Smits,Peter Hohenstein,Riccardo Fodde	58
8	Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin 2004 ·Oncogene ·Els C. Robanus-Maandag,Marco Giovannini,Martin van der Valk,Michiko Niwa‐Kawakita,Vincent Abramowski,Cristina Antonescu,Gilles Thomas,Anton Berns	20
9	Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130 2004 ·Genes & Development ·Jan‐Hermen Dannenberg,Leontine Schuijff,Marleen Dekker,Martin van der Valk,Hein te Riele	113
10	Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas 2004 ·Oncogene ·Vassiliki Theodorou,Mandy Boer,Britta Weigelt,Jos Jonkers,Martin van der Valk,John Hilkens	53
11	Receptor protein tyrosine phosphatase mu expression as a marker for endothelial cell heterogeneity; analysis of RPTPmu gene expression using LacZ knock-in mice 2003 ·The International Journal of Developmental Biology ·(unknown),Susana M. Chuva de Sousa Lopes,(unknown),Hans A.R. Bluyssen,Martin van der Valk,Emile E. Voest,Christine L. Mummery,Wouter H. Moolenaar,Martijn F.B.G. Gebbink	30
12	Oxygen Depletion during and after mTHPC-Mediated Photodynamic Therapy in RIF1 and H-MESO1 Tumors 2003 ·Radiation Research ·Hugo Schouwink,Hugo Oppelaar,Marjan Ruevekamp,Martin van der Valk,Guus Hart,Paul F.J.W. Rijken,Paul Baas,Fiona A. Stewart	22
13	Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancerbreakdown → 2001 ·Nature Genetics ·Jos Jonkers,Ralph Meuwissen,Hanneke van der Gulden,Hans Peterse,Martin van der Valk,Anton Berns	794
14	Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene 2001 ·Oncogene ·Ralph Meuwissen,Sabine C. Linn,Martin van der Valk,Wolter J. Mooi,Anton Berns	148
15	In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3 1999 ·Mechanisms of Development ·Jos Jonkers,Renée van Amerongen,Martin van der Valk,Els C. Robanus-Maandag,Miranda Molenaar,Olivier Destrée,Anton Berns	32
16	Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein 1999 ·Genes & Development ·Marco Giovannini,Els C. Robanus-Maandag,Michiko Niwa‐Kawakita,Martin van der Valk,James M. Woodruff,Laurence Goutebroze,P. Merel,A. Berns,Gilles Thomas	105
17	Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression 1999 ·Oncogene ·Jos Jonkers,Jan J. Weening,Martin van der Valk,(unknown),Anton Berns	28
18	Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse 1998 ·Oncogene ·Marc Vooijs,Martin van der Valk,Hein te Riele,Anton Berns	122
19	Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc 1997 ·Oncogene ·John Allen,Els Verhoeven,Jos Domen,Martin van der Valk,A. Berns	135
20	Requirement for a functional Rb-1 gene in murine developmentbreakdown → 1992 ·Nature ·Alan R. Clarke,(unknown),(unknown),Nathalie M. T. van der Lugt,Martin van der Valk,Martin Hooper,Anton Berns,(unknown)	840

About Martin van der Valk

Martin van der Valk is a scholar working on Oncology, Biotechnology and Pathology and Forensic Medicine, having authored 45 papers that have together received 6.9k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (7 papers), Drug Transport and Resistance Mechanisms (7 papers) and Pharmacological Effects and Toxicity Studies (6 papers). The work is most often cited by research in Oncology (3.6k citations), Molecular Biology (4.0k citations) and Cancer Research (703 citations). Martin van der Valk has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Anton Berns, Hein te Riele, Anton Berns, Ralph Meuwissen, Jos Jonkers, Els C. Robanus-Maandag, Hanneke van der Gulden, Hans Peterse, Jos Domen and Nathalie M. T. van der Lugt. Their work appears in journals such as Nature, Journal of Clinical Investigation and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact